<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34952382</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5905</ISSN><JournalIssue CitedMedium="Internet"><Volume>280</Volume><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Biomaterials</Title><ISOAbbreviation>Biomaterials</ISOAbbreviation></Journal><ArticleTitle>Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>121311</StartPage><MedlinePgn>121311</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biomaterials.2021.121311</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0142-9612(21)00667-0</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease of motor neurons leading to death within 3 years and without a curative treatment. Neurotrophic growth factors (NTFs) are pivotal for cell survival. A reason for the lack of patient efficacy with single recombinant NTF brain infusion is likely to be due to the synergistic neuroprotective action of multiple NTFs on a diverse set of signaling pathways. Fractionated (protein size &lt;50, &lt;30, &lt;10, &lt;3&#xa0;kDa) heat-treated human platelet lysate (HHPL) preparations were adapted for use in brain tissue with the aim of demonstrating therapeutic value in ALS models and further elucidation of the mechanisms of action. In neuronal culture all fractions induced Akt-dependent neuroprotection as well as a strong anti-apoptotic and anti-ferroptotic action. In the &lt;3&#xa0;kDa fraction anti-ferroptotic properties were shown to be GPX4 dependent highlighting a role for other platelet elements associated with NTFs. In the SOD1<sup>G86R</sup> mouse model, lifespan was strongly increased by intracerebroventricular delivery of HHPL or by intranasal administration of &lt;3&#xa0;kDa fraction. Our results suggest that the platelet lysate biomaterials are neuroprotective in ALS. Further studies would now validate theragnostic biomarker on its antiferroptotic action, for further clinical development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gouel</LastName><ForeName>Flore</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France. Electronic address: flore.gouel@chru-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmerman</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gosset</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INM, Univ Montpellier, Inserm, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raoul</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INM, Univ Montpellier, Inserm, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutheil</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonneaux</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gar&#xe7;on</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPECS-IMPact de l'Environnement Chimique sur la Sant&#xe9;, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danel-Brunaud</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duce</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0AH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnouf</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering &amp; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devedjian</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France; Universit&#xe9; du Littoral C&#xf4;te d'Opale, Calais, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LilNCog (JPARC), Lille Neurosciences &amp; Cognition, F-59000, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Biomaterials</MedlineTA><NlmUniqueID>8100316</NlmUniqueID><ISSNLinking>0142-9612</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motoneuron</Keyword><Keyword MajorTopicYN="N">Neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">Neuroprotection</Keyword><Keyword MajorTopicYN="N">Neurotrophic growth factors</Keyword><Keyword MajorTopicYN="N">Platelet biomaterials</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>20</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34952382</ArticleId><ArticleId IdType="doi">10.1016/j.biomaterials.2021.121311</ArticleId><ArticleId IdType="pii">S0142-9612(21)00667-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>